Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
Aim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxici...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2023-01-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/5020 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849401356266242048 |
|---|---|
| author | E. V. Grakova K. V. Kopeva S. N. Shilov E. N. Berezikova A. A. Popova M. N. Neupokoeva E. T. Ratushnyak V. V. Kalyuzhin A. T. Teplyakov |
| author_facet | E. V. Grakova K. V. Kopeva S. N. Shilov E. N. Berezikova A. A. Popova M. N. Neupokoeva E. T. Ratushnyak V. V. Kalyuzhin A. T. Teplyakov |
| author_sort | E. V. Grakova |
| collection | DOAJ |
| description | Aim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxicity (AIC) without prior cardiovascular diseases (CVD) during 12-month follow-up.Materials and methods. A total of 82 women (average age 45.0 (42.0; 50.0) years) with AIC and without prior CVD were included in the study. Echocardiography was performed and serum levels of NT-proBNP were determined at baseline and at 12 months after the enrollment. Gene polymorphisms in ADRB1 and ACE genes were evaluated by polymerase chain reaction at baseline.Results. Carriers of the G/G genotype in the ADRB1 gene and G/G genotype in the ACE (I/D, rs4343) gene showed a significant increase in left ventricular ejection fraction (LVEF), a decrease in the size of the left ventricle (LV) and left atrium (LA), and a fall in the NT-proBNP level. Carriers of other genotypes had further progression of AIC which was manifested through a decrease in LVEF and an increase in the size of LV and LA.Conclusion. Evaluation of gene polymorphisms in ADRB1 (Arg389Gly, rs1801253) and ACE (I/D, rs4343) genes may be recommended before treatment initiation for AIC in women without prior CVD to determine who will benefit from carvedilol and enalapril therapy, as well as to identify a priority group of patients for personalized intensification and optimization of treatment for decreasing development of adverse cardiovascular events. |
| format | Article |
| id | doaj-art-d716a486ddc14e388bcef4acedb28443 |
| institution | Kabale University |
| issn | 1682-0363 1819-3684 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj-art-d716a486ddc14e388bcef4acedb284432025-08-20T03:37:46ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842023-01-01214445310.20538/1682-0363-2022-4-44-532940Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseasesE. V. Grakova0K. V. Kopeva1S. N. Shilov2E. N. Berezikova3A. A. Popova4M. N. Neupokoeva5E. T. Ratushnyak6V. V. Kalyuzhin7A. T. Teplyakov8Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of SciencesCardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of SciencesNovosibirsk State Medical University (NSMU)Novosibirsk State Medical University (NSMU)Novosibirsk State Medical University (NSMU)Novosibirsk State Medical University (NSMU)Novosibirsk State Medical University (NSMU)Siberian State Medical University (SSMU)Cardiology Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of SciencesAim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxicity (AIC) without prior cardiovascular diseases (CVD) during 12-month follow-up.Materials and methods. A total of 82 women (average age 45.0 (42.0; 50.0) years) with AIC and without prior CVD were included in the study. Echocardiography was performed and serum levels of NT-proBNP were determined at baseline and at 12 months after the enrollment. Gene polymorphisms in ADRB1 and ACE genes were evaluated by polymerase chain reaction at baseline.Results. Carriers of the G/G genotype in the ADRB1 gene and G/G genotype in the ACE (I/D, rs4343) gene showed a significant increase in left ventricular ejection fraction (LVEF), a decrease in the size of the left ventricle (LV) and left atrium (LA), and a fall in the NT-proBNP level. Carriers of other genotypes had further progression of AIC which was manifested through a decrease in LVEF and an increase in the size of LV and LA.Conclusion. Evaluation of gene polymorphisms in ADRB1 (Arg389Gly, rs1801253) and ACE (I/D, rs4343) genes may be recommended before treatment initiation for AIC in women without prior CVD to determine who will benefit from carvedilol and enalapril therapy, as well as to identify a priority group of patients for personalized intensification and optimization of treatment for decreasing development of adverse cardiovascular events.https://bulletin.ssmu.ru/jour/article/view/5020anthracycline-induced cardiotoxicityheart failuregene polymorphismsβ-blockerangiotensin-converting enzyme inhibitor |
| spellingShingle | E. V. Grakova K. V. Kopeva S. N. Shilov E. N. Berezikova A. A. Popova M. N. Neupokoeva E. T. Ratushnyak V. V. Kalyuzhin A. T. Teplyakov Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases Бюллетень сибирской медицины anthracycline-induced cardiotoxicity heart failure gene polymorphisms β-blocker angiotensin-converting enzyme inhibitor |
| title | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_full | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_fullStr | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_full_unstemmed | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_short | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_sort | pharmacogenetics in treatment of anthracycline induced cardiotoxicity in women without prior cardiovascular diseases |
| topic | anthracycline-induced cardiotoxicity heart failure gene polymorphisms β-blocker angiotensin-converting enzyme inhibitor |
| url | https://bulletin.ssmu.ru/jour/article/view/5020 |
| work_keys_str_mv | AT evgrakova pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT kvkopeva pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT snshilov pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT enberezikova pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT aapopova pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT mnneupokoeva pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT etratushnyak pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT vvkalyuzhin pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT atteplyakov pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases |